INSIGHTS ON CLINICAL TRIAL PARTNERING

• How A Strategic Bioanalysis CRO Partnership Empowers Sponsors

  Choosing the right bioanalysis CRO is vital to avoid costly delays. Sponsors need evaluation strategies that prioritize proven quality, predictable timelines, and submission-ready data.

• Advantages Of Sourcing Biosimilars Vs. Branded Biologics In Clinical Trials

  Evaluate biosimilar alternatives during clinical trial planning to reduce comparator drug costs and improve overall study efficiency without compromising trial integrity.

• 8 Critical Questions To Ask Your IRB

  This article outlines eight essential questions to ask a potential IRB partner to assess their ability to help you navigate complex regulatory requirements while avoiding delays.

• 2026 State Of Clinical Trial Technology: The Five Strategic Imperatives

  AI acceleration and digital fragmentation are reshaping clinical trials. Discover five imperatives driving interoperability, smarter site enablement, and data‑ready workflows for future‑ready operations.

• Clinical, Commercial Packaging: Delivering Next-Gen Therapies

  4/7/2026

  See how strategic, agile, and sustainable packaging is transforming drug delivery into a key driver of speed, safety, and patient-centric innovation.

• Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO

  9/2/2025

  In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional; it is essential to survival and success.

• Clinical Trial Travel Reimbursements Keep Research Moving

  2/4/2026

  Fair, transparent reimbursement systems improve accessibility, trust, and study retention. Clear, timely travel payments strengthen research participation and ease site administrative strain.

• Improving Site Efficiency With Automated Drug Resupply And Forecasting

  8/22/2025

  Interactive Response Technology (IRT) can transform site operations by replacing error-prone manual processes with real-time, automated systems that relieve some of the burden on trial sites.

• Case Management Accelerates Shipment For SCN1A+ Dravet Syndrome Gene Therapy

  3/12/2026

  Consider this streamlined, end-to-end solution that helped safeguard study timelines and ensured that patients with urgent medical needs could receive treatment without delay.